Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
TRML
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-0.20
vs -0.00
Q3.23
N/A
-1.64
vs -0.00
Q4.23
N/A
-0.81
vs -0.00
Q1.24
N/A
-0.55
vs -0.37
Q2.24
N/A
-0.68
vs -0.20
Q3.24
N/A
-0.78
vs -1.64
Q4.24
N/A
-0.86
vs -0.81
Q1.25
N/A
-0.89
vs -0.55
Q2.25
N/A
-0.92
vs -0.68
Q3.25
N/A
-0.94
vs -0.78
Sales Growth
YoY
Current
Estimates
Q4.22
NA
NA vs NA
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
2.3M vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
-98%
40K vs 2.3M
Q1.25
NA
NA vs NA
Return on Equity
QoQ
Q2.23
+38%
0.38
vs -0.05
Q3.23
-5%
-0.05
vs 0.38
Q4.23
+1%
0.01
vs -0.05
Q1.24
-4%
-0.04
vs 0.01
Q2.24
-5%
-0.05
vs -0.04
Q3.24
-6%
-0.06
vs -0.05
Q4.24
-7%
-0.07
vs -0.06
Q1.25
-8%
-0.08
vs -0.07
Institutionnal Ownership
QoQ
Q4.23
54
54
vs NA
NA
Q1.24
105
105
vs 54
94%
Q2.24
86
86
vs 105
-18%
Q3.24
92
92
vs 86
7%
Q4.24
100
100
vs 92
9%
globenewswire.com
7 hours ago
globenewswire.com
7 hours ago
globenewswire.com
7 hours ago
globenewswire.com
7 hours ago
globenewswire.com
7 hours ago
Relative Strength
TRML
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How TRML compares to sector?
TRML
-5x
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
NASDAQ
Unprofitable
Unprofitable
0.35 ( 2.27%)
Relative Strenght
37
Volume Buzz
-63%
Earning Acce
No
Dist 52w H.
47%Forecast
NaN%2026-Revenue
-365%2026-EPS
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
46.00(192.25%)
Number of analyst
2
Last analyst upgrade/downgrade
Wedbush
initialisePrevious: Not converted
2025-03-06
Now: Outperform
BMO Capital
initialisePrevious: Not converted
2024-12-05
Now: Outperform
Cantor Fitzgerald
initialisePrevious: Not converted
2024-10-15
Now: Overweight
